Immune thrombocytopenic purpura secondary to tuberculosis
نویسندگان
چکیده
منابع مشابه
Immune thrombocytopenic purpura secondary to endometriosis.
In this paper, we describe a patient with immune thrombocytopenic purpura (ITP) secondary to endometriosis. To our knowledge, this is the first reported case presenting such an association. Surgical eradication of the endometriosis was the only effective treatment for the thrombocytopenia. The pathogenic connection between both disorders seems to be an altered immune function.
متن کاملImmune Thrombocytopenic Purpura Associated with Pulmonary Tuberculosis
A 22-year-old woman was admitted into our hospital because of generalized purpura and abnormalities in her chest X-ray. Isolated thrombocytopenia and elevated platelet-associated IgG levels were detected, while the bone marrow examination was normal. Mycobacterium tuberculosis was detected in the bronchoalveolar lavage fluid, and consequently she was diagnosed as having active tuberculosis. Hig...
متن کاملimmune thrombocytopenic purpura and hemolytic anemia secondary to hepatitis a
hepatitis a is common in children and usually is a self-limiting disease. although extrahepatic and hematological immune manifestations following acute hepatitis a virus (hav) infection have rarely been reported, they are frequently observed in other viral hepatitis. in this paper, we report the case of a 3-year-old girl who developed immune thrombocytopenic purpura (itp) and hemolytic anemia ...
متن کاملAcute Immune Thrombocytopenic Purpura in Infants
Abstract Objective Immune thrombocytopenic purpura (ITP) manifests as an easy bruising or extravasation of blood from capillaries into skin and mucous membranes. The characteristics of acute ITP in infants have rarely been described. In order to better understand acute ITP in infants, the characteristics of the disease at this age group was investigated. Material and Methods The present des...
متن کاملDrug-induced immune thrombocytopenic purpura secondary to sunitinib
SUNITINIB (SUTENT: Pfizer, New York, NY, U.S.A.) is an oral multi-targeted tyrosine kinase inhibitor approved for use in various solid tumour malignancies. Many side effects secondary to sunitinib have been documented. In particular, sunitinib administration is known to result in thrombocytopenia, with the cause being attributed to myelosuppression. Here, we present the first case report to dem...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Contemporary Pediatrics
سال: 2018
ISSN: 2349-3291,2349-3283
DOI: 10.18203/2349-3291.ijcp20183549